Actively Recruiting
Biomarkers and Imaging Markers Screening for Intracerebral Hemorrhage Patients
Led by Southwest Hospital, China · Updated on 2024-06-17
200
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Intracerebral hemorrhage (ICH) is a serious type of stroke that causes high death rates and long-term disability. Researchers are investigating molecular and imaging markers to improve understanding of ICH diagnosis, treatment decisions, and prognosis. This observational study aims to find potential biomarkers from body samples and imaging scans to help with early warning, diagnosis, therapy monitoring, risk assessment, intervention, and outcome prediction in ICH patients. Participants include people diagnosed with spontaneous ICH confirmed by CT within 72 hours of symptom onset, along with healthy volunteers matched by age and sex. Samples such as blood, cerebral spinal fluid, urine, saliva, and possibly tissue will be collected. Imaging scans like CT, MRI, magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) will be performed repeatedly to detect imaging markers. During the study, researchers will collect body samples and conduct serial imaging scans to analyze biomarkers and imaging features within one month of onset. They will assess outcomes using scales like the Glasgow Outcome Scale Extended and modified Rankin scale at one year. The study includes monitoring brain imaging and clinical evaluations to better understand ICH progression and recovery over time.
CONDITIONS
Brief Title
Biomarkers and Imaging Markers for ICH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals aged 18 to 80 years
- Hematoma size is more than 5 ml
- Evidence of spontaneous intracerebral hemorrhage on CT scan
- Patient within 72 hours of symptom onset
- Glasgow Coma Scale score between 5 and 15
- History of hypertension
You will not qualify if you...
- Individuals younger than 18 years or older than 80 years
- Hemorrhage caused by aneurysm, arteriovenous malformation, or other cerebrovascular diseases
- Intracerebral hemorrhage secondary to tumor or trauma
- Effects of previous anticoagulants not fully reversed
- Severe dysfunction of heart, lungs, kidneys, liver, autoimmune diseases, or other organs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Within 1 month of symptom onset
Participants undergo collection of body samples such as blood, cerebral spinal fluid, urine, saliva, and imaging scans including CT, MRI, MRS, and PET to identify biomarkers and imaging markers.
Multiple visits for sample collection and imaging scans within 1 month
Duration - 1 year
Participants are followed for long-term outcomes including assessments of neurological function and recovery.
Assessments at 1 year
Trial Site Locations
Total: 1 location
1
Department of Neurosurgery , Southwest Hospital, Third Military Medical University,
Chongqing, Chongqing Municipality, China, 400038
Actively Recruiting
Research Team
R
Rong Hu, Ph.D
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here